RICHLAND, WA, 14 December 2015 – IsoRay Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the recent publication of the peer-reviewed results of a study entitled: “Neurocognitive function and quality of life in patients with newly diagnosed metastasis after treatment with intra-operative cesium-131 brachytherapy: a prospective trial.”
Twenty-four patients with newly diagnosed metastasis to the brain were treated with Cs-131 brachytherapy seeds after surgical resection between 2010 and 2012. Study protocols required physician administered mini-mental status examinations (MMSE) and functional assessment of cancer brain therapy (FACT-Br) questionnaires to all patients before treatment, and again every 2 months for a 6 month period, with a final follow-up at 12 months. Results of the study suggest that surgical resection with intraoperative Cs-131 brachytherapy is able to “stabilize or improve NCF [neurocognitive function] for patients with metastatic brain tumors by improving control of brain tumors and avoiding the toxicity of WBRT [whole brain radiotherapy].”
The study was presented at ASTRO’s 56th Annual Meeting in San Francisco, CA, on September 16, 2014. The research paper was published online on December 9, 2015 in the Journal of Neuro-Oncology (Pham, Anthony, et. al., “Neurocognitive function and quality of life in patients with newly diagnosed brain metastasis after treatment with intra-operative cesium-131 brachytherapy: a prospective trial,” p.1-9.) and is available at – http://link.springer.com/article/10.1007/s11060-015-2009-5.
Ad Statistics
Times Displayed: 50213
Times Visited: 1424 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
Dwight Babcock, IsoRay’s Chairman and CEO, stated: “This study suggests that surgical resection with intraoperative Cs-131 has the capacity to preserve or even improve quality of life after treatment in the short-term. This is encouraging and we look forward to the results of a comprehensive, longitudinal multi-center study, which is currently underway. We thank Weill Cornell Medical College and the authors of this study for their ongoing work in cancer research and Cs-131’s potential applications. ”
About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us on Twitter @Isoray.
Back to HCB News
